Sangamo Therapeutics Inc [SGMO] stock is trading at $1.17, down -4.88%. An important factor to consider is whether the stock is rising or falling in short-term value. The SGMO shares have gain 3.54% over the last week, with a monthly amount glided 14.71%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sangamo Therapeutics Inc [NASDAQ: SGMO] stock has seen the most recent analyst activity on December 13, 2024, when Truist upgraded its rating to a Buy but kept the price target unchanged to $7 for it. Previously, H.C. Wainwright reaffirmed its Buy rating on December 10, 2024, and kept the price target unchanged to $10. On November 03, 2023, downgrade downgraded it’s rating to Sector Perform and revised its price target to $2 on the stock. BofA Securities downgraded its rating to a Underperform and decreased its price target to $1.50 on April 28, 2023. Wedbush upgraded its rating to a Outperform but $16 remained the price target by the analyst firm on February 27, 2023. BofA Securities downgraded its rating to Neutral for this stock on January 06, 2023, and downed its price target to $5.
Sangamo Therapeutics Inc [SGMO] stock has fluctuated between $0.30 and $3.18 over the past year. Currently, Wall Street analysts expect the stock to reach $2.5 within the next 12 months. Sangamo Therapeutics Inc [NASDAQ: SGMO] shares were valued at $1.17 at the most recent close of the market. An investor can expect a potential return of 113.68% based on the average SGMO price forecast.
Analyzing the SGMO fundamentals
Sangamo Therapeutics Inc [NASDAQ:SGMO] reported sales of 52.29M for the trailing twelve months, which represents a growth of 425.77%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -2.57%, Pretax Profit Margin comes in at -2.58%, and Net Profit Margin reading is -2.58%. To continue investigating profitability, this company’s Return on Assets is posted at -1.21, Equity is -2.66 and Total Capital is -1.97. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.71.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1217 points at the first support level, and at 1.0733 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.2367, and for the 2nd resistance point, it is at 1.3033.
Ratios To Look Out For
For context, Sangamo Therapeutics Inc’s Current Ratio is 1.35. On the other hand, the Quick Ratio is 1.35, and the Cash Ratio is 0.91. Considering the valuation of this stock, the price to sales ratio is 4.67, the price to book ratio is 6.24.
